|Disease Group:||Breast; Cervix; Colon; Colorectal; Endometrial; Esophageal; Gallbladder; Gastric; Gastrointestinal; Genitourinary; Gynecology; Head And Neck; Kidney; Liver; Lung; Lymphoma; Melanoma; Pancreas; Prostate; Rectum; Sarcoma; Small Bowel; Testis; Unknown Primary; Uterus|
|Phase of Study:||Phase I|
|Treatment Location:||Only at MDACC|
|Estimated Length of Stay in Houston:||Patients will be admitted for approximately 5-7 days until recovery from all |
immediate treatment related toxicities
|Return Visit:||Patients will return to MDACC for a clinical evaluation on a monthly basis|
|Home Care:||The initial or loading doses of liposomal doxorubicin will be given in the |
clinic. Subsequent doses may be given at home.